Verrica Pharmaceuticals (VRCA) EBIAT (2021 - 2025)
Verrica Pharmaceuticals has reported EBIAT over the past 5 years, most recently at -$8.1 million for Q4 2025.
- Quarterly results put EBIAT at -$8.1 million for Q4 2025, up 50.17% from a year ago — trailing twelve months through Dec 2025 was -$17.9 million (up 76.64% YoY), and the annual figure for FY2025 was -$17.9 million, up 76.64%.
- EBIAT for Q4 2025 was -$8.1 million at Verrica Pharmaceuticals, down from -$274000.0 in the prior quarter.
- Over the last five years, EBIAT for VRCA hit a ceiling of $204000.0 in Q2 2025 and a floor of -$24.8 million in Q3 2023.
- Median EBIAT over the past 5 years was -$10.0 million (2022), compared with a mean of -$11.1 million.
- Biggest five-year swings in EBIAT: plummeted 29981.93% in 2023 and later surged 101.19% in 2025.
- Verrica Pharmaceuticals' EBIAT stood at -$9.5 million in 2021, then soared by 37.82% to -$5.9 million in 2022, then plummeted by 314.94% to -$24.6 million in 2023, then surged by 34.18% to -$16.2 million in 2024, then soared by 50.17% to -$8.1 million in 2025.
- The last three reported values for EBIAT were -$8.1 million (Q4 2025), -$274000.0 (Q3 2025), and $204000.0 (Q2 2025) per Business Quant data.